Related Experiment Video
Updated: Aug 9, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Platelet hyperaggregability to platelet activating factor (PAF) in non-ST elevation acute coronary syndromes
L K Michalis1, A P Tambaki, C S Katsouras
1Department of Cardiology, University Hospital of Ioannina, Greece. lmihalis@cc.uoi.gr
Current Medical Research and Opinion
|May 23, 2002
Summary
Platelet hyperaggregability to platelet-activating factor (PAF) is a sensitive and specific indicator in non-ST elevation acute coronary syndromes. This heightened response may contribute to the condition's underlying mechanisms.
Area of Science:
- Cardiology
- Hematology
- Biochemistry
Background:
- Myocardial ischemia is known to enhance platelet aggregation ex vivo.
- Platelet activation plays a crucial role in acute coronary syndromes.
Purpose of the Study:
- To investigate platelet aggregatory response to platelet-activating factor (PAF) in patients with non-ST elevation acute coronary syndromes (NSTE-ACS).
- To determine the diagnostic specificity and sensitivity of this response for NSTE-ACS.
Main Methods:
- Studied 32 NSTE-ACS patients and 20 healthy volunteers.
- Measured platelet aggregation in platelet-rich plasma using PAF (100 nM) ex vivo.
- Determined PAF EC50 values and maximal aggregation percentages.
Main Results:
- NSTE-ACS patients exhibited significantly lower PAF EC50 values (p < 0.0001) and higher maximal aggregation percentages (p < 0.0005) compared to controls.
- PAF EC50 values achieved 91.2% sensitivity and 90.0% specificity for NSTE-ACS.
- Maximal aggregation percentage showed 87.5% sensitivity and 70.0% specificity.
Conclusions:
- Platelet hyperaggregability to PAF ex vivo is a highly specific and sensitive characteristic of NSTE-ACS.
- This platelet dysfunction may be a contributing factor to the pathophysiology of NSTE-ACS.
Related Concept Videos
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:30Peripheral Artery Disease I: Introduction
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...